We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Second Test Helps Prevent Incorrect HIV Diagnosis

By LabMedica International staff writers
Posted on 06 Dec 2017
Print article
The specificity of nucleic acid amplification tests (NAATs) used for early infant diagnosis (EID) of human immunodeficiency virus (HIV) infection is less than 100%, leading some HIV-uninfected infants to be incorrectly identified as HIV-infected.

Without confirmatory testing, 128 of every 1000 infants initiating antiretroviral therapy (ART) were actually HIV-uninfected, due to false-positive diagnoses; with confirmatory testing, only 1 out of 1,000 infants initiating ART was truly uninfected.

A team of scientists working under the auspices of the University of Cape Town (Cape Town, South Africa) examined the impact of a second NAAT in infants to confirm a first positive result. They assumed a NAAT cost of USD 25, specificity of 99.6%, and sensitivity of 100%. The team used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)–Pediatric model, and simulated EID testing at age six weeks for HIV-exposed infants without and with confirmatory testing. After diagnosis, infants were linked to and retained in care for 10 years (false-positive) or lifelong (true-positive).

Both without and with confirmatory testing, life-expectantly (LE) was 26.2 years for HIV-infected infants and 61.4 years for all HIV-exposed infants; clinical outcomes for truly infected infants did not differ by strategy. Because confirmatory testing averted costly HIV care and ART in truly HIV-uninfected infants, it was cost-effective: total cost USD 1,790/infant tested, compared to USD 1,830/infant tested without confirmatory testing. Confirmatory testing remained cost-effective unless NAAT cost exceeded USD 400 or the HIV-uninfected status of infants incorrectly identified as infected was ascertained and ART stopped within three months of starting.

Andrea Ciaranello, MD, MPH, an assistant professor at Massachusetts General Hospital (Boston, MA, USA) and senior author of the study, said, “While projected cost differences are small, confirmatory testing is likely to be cost-saving under a wide range of scenarios in South Africa. Concerns about the cost of the second test itself should not be the reason to avoid this important intervention.” The study was published on November 21, 2017, in the journal Public Library of Science Medicine.

Related Links:
University of Cape Town
Massachusetts General Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.